Kestra Medical Technologies Ltd

Kestra Medical Technologies Ltd(KMTS)の株式分析

$29.370

+2.297 (+7.82%)終値時点

Loading chart…
高値
29.750
始値
27.310
出来高加重平均価格
28.72
出来高
638.78K
時価総額
—
安値
27.030
売買代金
18.34M
EV/EBITDA(TTM)
-7.12

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.

AI分析 of Kestra Medical Technologies Ltd (KMTS)

買い

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

バリュエーション指標

Kestra Medical Technologies Ltd(KMTS)の現在の予想PERは0.00で、5年平均は-9.68です。

予想PER

大幅な割高
5年平均 P/E
-9.68
現在のP/E
0.00
割高
-6.54
割安
-12.82

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-10.35
現在のEV/EBITDA
-7.12
割高
-4.05
割安
-16.64

予想PSR

適正
5年平均 P/S
10.76
現在のP/S
8.28
割高
14.13
割安
7.38

KMTS を保有するクジラ

J

Jaunty Global Limited

+ を保有KMTS

-1.64%

3か月リターン

イベントタイムライン

2026-09-15 (ET)

09:00:00

Stock Futures Lower Ahead of Fed Policy Meeting

2026-09-14 (ET)

19:30:00

Anthropic CEO Warns of Out-of-Control AI, Tech Stocks Plunge

17:00:00

Kestra Medical Shares Down 7% to $22.32 After Q1 Earnings Miss

16:30:00

Kestra Raises FY27 Revenue Guidance to $141 Million

16:30:00

Kestra Reports Q1 Revenue of $30.97M, Exceeding Expectations

ニュース

KMTS のよくある質問 — Alphio AI が回答

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める